Risk Factors | OR (95% CI) | p | HR (95% CI) | p |
---|---|---|---|---|
Age | 1.01 (0.90–1.14) | 0.845 | 1.01 (0.91–1.12) | 0.878 |
ISN/RPS class III or IV, LN | 0.55 (0.04–6.89) | 0.644 | 0.32 (0.03–3.58) | 0.358 |
Acute aPLN | 7.2 (0.58–90.5) | 0.124 | 6.71 (0.61–74.0) | 0.120 |
Baseline eGFR, for each 10-ml/min/1.73m2 increase | 0.56 (0.29–1.09) | 0.088 | 0.62 (0.36–1.05) | 0.073 |
Baseline proteinuria, for each 1.0-g/day increase | 1.28 (0.99–1.66) | 0.057 | 1.20 (1.00–1.45) | 0.046 |
Baseline MAP, for each 10-mmHg increase | 1.53 (0.80–2.93) | 0.198 | 1.43 (0.82–2.49) | 0.210 |
Kidney disease progression is defined as 30% decline of eGFR or ESKD without remission until the end of followup. Data in bold face are statistically significant. RASI: renin-angiotensin system inhibitor; SLE: systemic lupus erythematosus; aPLN: antiphospholipid-associated nephropathy; ISN/RPS: International Society of Nephrology/Renal Pathology Society; LN: lupus nephritis; eGFR: estimated glomerular filtration rate; MAP: mean arterial pressure; ESKD: endstage kidney disease.